In the FINE-ONE trial, finerenone met its primary endpoint by significantly reducing the urinary albumin-to-creatinine ratio by 25% compared with placebo over 6 months in adults with T1D and CKD. The ...
Bayer (BAYRY) (BAYZF) announced on Thursday that the U.S. Food and Drug Administration has granted priority review for its marketing application seeking a label expansion for its kidney disease ...
May 21 (Reuters) - Bayer (BAYGn.DE), opens new tab said on Thursday that the U.S. Food and Drug Administration had accepted its supplemental New Drug Application for finerenone and granted priority ...
“Secondary stroke remains a serious and persistent challenge, and the FDA’s Priority Review designation underscores the urgency of advancing potential new approaches in secondary stroke prevention,” ...
New funding will examine more than fifteen years of reports to identify missed opportunities to protect women. The work follows fresh national concerns over domestic abuse related deaths. Americans ...
Rocket says the PRV sale extends its cash runway into the second quarter of 2028. (dima_zel/iStock/Getty Images Plus) Rocket Pharmaceuticals has offloaded its lucrative FDA rare pediatric disease ...
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare ...
The Food and Drug Administration (FDA) on Friday granted fast-track review to three companies studying psychedelic therapies to treat depression and post-traumatic stress disorder (PTSD), the latest ...
Forbes contributors publish independent expert analyses and insights. Christine Ro is a journalist covering science and development. Occasionally I’ll go watch a TV show taping. Big-name shows are ...
Composition of Health Care Contact Days and Mortality Prediction Among Older Adult Clinical Trial Participants In this cross-sectional study, we used US Food and Drug Administration’s (FDA), European ...
A Prescription Drug User Fee Act target date of September 27, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results